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Am J KidneA Randomized, Single-Blind, Crossover Trial of Recovery Time in
High-Flux Hemodialysis and Hemodiafiltration
James R. Smith, MBChB,1,2 Norica Zimmer, MD,1 Elizabeth Bell, MSc,1
Bernard G. Francq, PhD,3 Alex McConnachie, PhD,3 and Robert Mactier, MD, FRCP1
Background: The choice between hemodiafiltration (HDF) or high-flux hemodialysis (HD) to treat end-stage
kidney disease remains a matter of debate. The duration of recovery time after treatment has been associated
with mortality, affects quality of life, and may therefore be important in informing patient choice. We aimed to
establish whether recovery time is influenced by treatment with HDF or HD.
Study Design: Randomized patient-blinded crossover trial.
Settings & Participants: 100 patients with end-stage kidney disease were enrolled from 2 satellite dialysis
units in Glasgow, United Kingdom.
Intervention: 8 weeks of HD followed by 8 weeks of online postdilution HDF or vice versa.
Outcomes: Posttreatment recovery time, symptomatic hypotension events, dialysis circuit clotting events,
and biochemical parameters.
Measurements: Patient-reported recovery time in minutes, incidence of adverse events during treatments,
hematology and biochemistry results, quality-of-life questionnaire.
Results: There was no overall difference in recovery time between treatments (medians for HDF vs HD of
47.5 [IQR, 0-240] vs 30 [IQR, 0-210] minutes, respectively; P5 0.9). During HDF treatment, there were
significant increases in rates of symptomatic hypotension (8.0% in HDF vs 5.3% in HD; relative risk [RR], 1.52;
95% CI, 1.2-1.9; P, 0.001) and intradialytic tendency to clotting (1.8% in HDF vs 0.7% in HD; RR, 2.7; 95%
CI, 1.5-5.0; P5 0.002). Serum albumin level was significantly lower during HDF (3.2 vs 3.3 g/dL; P , 0.001).
Health-related quality-of-life scores were equivalent.
Limitations: Single center; mean achieved HDF convection volume, 20.6 L.
Conclusions: Patients blinded to whether they were receiving HD or HDF in a randomized controlled
crossover study reported similar posttreatment recovery times and health-related quality-of-life scores.
Am J Kidney Dis. -(-):---. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
INDEX WORDS: Hemodialysis (HD); high-flux HD; hemodiafiltration (HDF); recovery time; intradialytic
hypotension; symptomatic hypotension; blood pressure; dialysis circuit clotting; dialysis modality; end-stage
kidney disease (ESKD); quality of life; randomized controlled trial (RCT).End-stage kidney disease has a significant anddeleterious impact on duration and quality of
life.1-4 Approximately 1.9 million patients receive
renal replacement therapy worldwide.5 Intermittent
renal replacement therapy remains essential for many,
and extracorporeal treatments for end-stage kidney
disease such as hemodialysis (HD) and hemodiafil-
tration (HDF) have a higher incidence and prevalence
than peritoneal dialysis, particularly in the developed
world.6-8
Observational data have suggested that HDF is
beneficial. However, randomized controlled trial (RCT)lasgow Renal and Transplant Unit, Queen Elizabeth
ospital, Glasgow; 2Centre for Inflammation Research,
f Edinburgh, Edinburgh; and 3Robertson Centre for
, University of Glasgow, Glasgow, Scotland, United
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gistration: www.ClinicalTrials.gov; study number:
79.
y Dis. 2016;-(-):---data comparing HDF with HD have produced mixed
results, with analyses (mainly post hoc) suggesting that
HDF has superior cardiovascular and mortality out-
comes limited to patients receiving the highest con-
vection volumes.9-14 Although this is encouraging, high
convection volumes may not be achievable in HDF
patients who have suboptimal vascular access and/or
time constraints associated with real-life dialysis
provision.15
Factors influencing patient preference and choice are
becoming more prominent. Patients treated with HD
have lower health-related quality-of-life (HRQoL)Address correspondence to James R. Smith, MBChB, Centre for
Inflammation Research, Queens Medical Research Institute,
University of Edinburgh, 47 Little France Crescent, Edinburgh,
EH16 4TJ. E-mail: jsmith82@nhs.net
 2016 The Authors. Published by Elsevier Inc. on behalf of the
National Kidney Foundation, Inc. This is an open access article





Smith et alscores than the general population, and this is associ-
ated with increased morbidity and mortality.16,17
Although some previous studies have shown an
improvement in HRQoL with convective treatments
compared to HD,3,4 the largest RCT to have studied this
outcome found no difference between HDF and low-
flux HD.9 Length of recovery time after dialysis is an
important patient-reported outcome measure that
adversely affects HRQoL, and evidence from the
Dialysis Outcomes and Practice Patterns Study
(DOPPS) cohort has suggested an association between
longer postdialysis recovery time and increased
mortality.18
We performed a patient-blinded randomized
crossover study of patient-reported recovery time to




A patient-blinded, randomized, controlled, crossover design was
used. Patients were randomly assigned in a 1:1 ratio to receive 8
weeks of HD followed immediately by 8 weeks of online post-
dilution HDF, or vice versa. Patients were recruited from 2 satellite
dialysis units (Stobhill Hospital and Glasgow Royal Infirmary) and
consented by E.B., N.Z., J.R.S., or R.M. The study ran from July
2013 through March 2014. Randomization was conducted by E.B.
using a remote telephone-based system run by the Robertson
Centre for Biostatistics, University of Glasgow, United Kingdom.
The study was conducted in accordance with the ethics princi-
ples of the Declaration of Helsinki; all patients provided written
informed consent. Good Clinical Practice guidelines were fol-
lowed throughout. The West of Scotland Research and Ethics
Committee approved the study (13/WS/0010). Anonymized data
were sent to the Robertson Centre for Biostatistics for analysis.
Data analysis programs were developed prior to the release of
randomization codes to the study statistician.
Patient Selection
There were 198 patients screened for eligibility. Inclusion
criteria were receiving HD for more than 90 days, reliable vascular
access, and age of 18 years or older. Exclusion criteria were
currently receiving HDF (however, no recruited patients ended up
having previous HDF exposure), life expectancy less than 6
months, active neoplasia, recent (within 1 month) emergency
hospital admission, and unable to give informed consent or com-
plete questionnaires. Of 119 patients meeting these criteria, 100
underwent randomization, stratified by age (4 strata: 18-49, 50-59,
60-69, and $70 years) and sex (given sex differences noted in
recovery time reporting18) into one of 2 groups: HD followed by
HDF, or HDF followed by HD. A separate randomization list was
generated for each stratum by a computer program, using the
method of randomized permuted blocks of length 4.
Treatments
Patients received 3 treatment sessions per week. Dialysis time,
dialyzer blood flow rate, dialysate flow rate, postdialysis weight,
and medications were kept constant unless changes were required
on clinical grounds. High-flux dialyzers (FX80 or FX100; Frese-
nius) were used to remain consistent with patients’ previous di-
alyzers and reduce the risk for inadvertent unblinding. Dialysate
composition was as follows: sodium, 138 mmol/L; potassium,
2 mmol/L; chloride, 108.5 mmol/L; bicarbonate, 32 mmol/L;2
acetate, 3 mmol/L; calcium, 1.25 mmol/L; magnesium, 0.5 mmol/
L; and glucose, 1 g/L. Fresenius 5008 dialysis machines were
used. To further ensure patient blinding, dialysis machines were
turned away and the on-screen treatment modality notification was
covered. Dialysis unit staff were not blinded to treatment
allocation.
Outcomes
The primary outcome was reported recovery time in minutes.
On arrival for each session, patients were asked by the treating
nurse to state how long it took them to recover completely from
the preceding session. Secondary outcomes were frequency of
symptomatic hypotension; frequency of intradialytic clotting
events; pre–dialysis session serum concentrations of potassium,
phosphate, vitamin B12, parathyroid hormone, b2-microglobulin,
betaine, and interleukin 6; and Kt/V of urea.
Measurement Methods
Predialysis hematologic and biochemical tests were performed
following a 1-day treatment gap. Blood results from the middle
and end point of each treatment period were used in the analysis.
The nurses administering treatments were responsible for doc-
umenting primary and secondary end point data, as well as routine
dialysis session duties and data collection.
Although not prespecified outcomes, the frequency of other
adverse events (documented in free-text format by nursing staff),
change in quality-of-life scores (Kidney Disease Quality of Life–
Short Form [KDQOL-SF], version 1.319), change in dialysis dose,
and patients’ preferred dialysis modality at the end of the study
were also recorded. This was overseen by a dedicated research
nurse, who also administered the KDQOL-SF, version 1.3, ques-
tionnaires and processed blood samples.
Sample Size Calculation
This was based on pilot data demonstrating the variation in
recovery times in 100 patients over 3 consecutive HD sessions. To
detect a 20% absolute reduction in recovery time with 90% power,
we calculated that 82 patients would need to complete the study
(41 in each group). We planned to randomly assign 100 patients in
total, allowing for a dropout rate of 18%.
Statistical Analyses
Analyses were performed on an intention-to-treat basis. Base-
line characteristics and Charlson comorbidity scores20 were
compared between groups (HD then HDF vs HDF then HD) by
Fisher exact tests for categorical variables and t tests for contin-
uous variables (or Wilcoxon tests if needed). Given that the dis-
tribution of recovery times was bimodal with a peak at zero,
recovery times were analyzed by crossover analysis with 2 mixed
models. A generalized linear mixed model (logistic regression
with random effect) was run to model the odds for a patient to
recover immediately (recovery time 5 0 minutes) and a mixed
model was run to model the delayed (recovery time . 0 minutes)
recovery times (after a logarithmic transformation). The models
were combined by Monte Carlo simulations, then a parametric
bootstrap method was used to obtain the overall P value.21 Cor-
relation between recovery times across successive sessions were
modeled with an autoregressive model of order 1 (in which each
recovery time is dependent on the previous session, and so on)
by treatment and time period. Additional analyses were run
for blood tests, dialysis data, Kt/V, and mean blood flow.
Hypotension, clotting, and adverse events were compared between
the treatments by relative risk (RR), and in order to take into ac-
count the crossover design, odds ratios (ORs) obtained by logistic
regression (with random effects) were also calculated. The
KDQOL survey was compared between treatments and baseline
with Friedman tests.Am J Kidney Dis. 2016;-(-):---
Recovery Time in HD Versus HDFRESULTS
Study Participants
Table 1 shows baseline characteristics of 100 pa-
tients randomly assigned to receive HD then HDF or
HDF then HD. Characteristics were generally repre-
sentative of a typical prevalent HD cohort in the
United Kingdom.22 Figure 1 gives an outline of the
study flow.
Clinical Treatment Parameters
Treatment time and blood flow rate remained
constant between HD and HDF (Table 2). Addition-
ally, ultrafiltration volumes were similar and the mean
convection volume for HDF treatments was 20.6 L.
Pretreatment systolic blood pressure (SBP) was
lower while participants were receiving HDF (143 vsTable 1. Baseline Characteristics of 100 Participants Rand
Characteristic All (N 5 100) HD
Female sex 39 (39)
Age, y 656 14




Central venous catheter 31 (31)
Antihypertensive medication use 66 (66)
SBP, mm Hgc 1436 20
DBP, mm Hgc 696 12
Post-HD weight, kgc 74 [62-87]







Waitlisted for transplant 21 (21)
White 99 (99)
Smoking status
Current smoker 27 (27)
Ex-smoker 30 (30)
Never smoked 43 (43)
Diabetes 26 (26)
Ischemic heart disease 37 (37)
Peripheral vascular disease 19 (19)
Stroke 17 (17)
History of neoplasia 7 (7)
Charlson comorbidity score 76 2
Note: Values for categorical variables are given as count (perce
deviation or, in the case of non-normally distributed data, median [in
Abbreviations: DBP, diastolic blood pressure; HD, high-flux hemod
ultrafiltration.
aP values derived from t test for continuous variable (or bWilcoxon
reported for all variables.
cMean of 3 months of dialysis data prior to randomization.
Am J Kidney Dis. 2016;-(-):---145 mm Hg; P 5 0.03); however, this difference was
not demonstrated posttreatment (Table 2).
Primary Outcome: Posttreatment Recovery Time of
HDF Versus HD
Recovery time data were available for 92% of all
sessions. Recovery time for one-third of available
sessions was reported as zero minutes (immediate),
resulting in a bimodal distribution. To account for
this, immediate and delayed (.0 minutes) recovery
times were analyzed using separate models, then
joined to obtain an overall P value, as described in
the Statistical Analyses section in Methods. This
demonstrated no overall difference in recovery time
between HDF and HD (median values of 47.5 [IQR,
0-240] and 30 [IQR, 0-210] minutes, respectively;
P 5 0.9). However, of interest, individual models foromly Assigned to HD Followed by HDF or Vice Versa
Then HDF (n 5 50) HDF Then HD (n 5 50) P a
20 (40) 19 (38) 0.9
65 6 15 66 6 13 0.6
38 [14-90] 27 [16-46] 0.3b
0.2
31 (62) 37 (74)
0 (0) 1 (2)
19 (38) 12 (24)
31 (62) 35 (70) 0.5
144 6 22 1426 18 0.7
67 6 12 70 6 11 0.3
76 [64-88] 71 [61-86] 0.2b
1,995 6 681 1,644 6 668 0.01
0.7
13 (26) 13 (26)
5 (10) 6 (12)
17 (34) 13 (26)
3 (6) 7 (14)
12 (24) 11 (22)
13 (26) 8 (16) 0.3
49 (98) 50 (100) 0.5
0.5
11 (22) 16 (32)
17 (34) 13 (26)
22 (44) 21 (42)
15 (30) 11 (22) 0.5
20 (40) 17 (34) 0.7
14 (28) 5 (10) 0.04
10 (20) 7 (14) 0.6
6 (12) 1 (2) 0.1
76 2 66 2 0.4b
ntage); values for continuous variables, as mean 6 standard
terquartile range].
ialysis; HDF, hemodiafiltration; SBP, systolic blood pressure; UF,
) and Fisher exact test for categorical variables; 100% of data is
3
Assessed for eligibility (n=198) 
Randomized (n=100) 
Excluded (n=98) 
- Met exclusion criteria (n=79) 
- Declined to give consent (n=18) 
- Other reasons (n=1) 
High-flux hemodialysis 
8-weeks (n=50) 
- Randomized but did not  
   start (admission) (n=1) 
- Withdrawal (n=1) 
- Death (n=2) 
Hemodiafiltraon 
8-weeks (n=50) 
- Randomized but did not  
   start (admission) (n=1) 
- Withdrawal (n=4) 
- Death (n=0) 
Hemodiafiltraon 
8-weeks (n=46) 
- Withdrawal (n=3) 
- Death (n=2) 
High-flux hemodialysis 
8-weeks (n=45) 
- Withdrawal (n=0) 
- Death (n=0) 
Completed (n=41) Completed (n=45) 
Figure 1. CONSORT (Consolidated Standards of Reporting
Trials) flow diagram.
Smith et alimmediate and delayed recovery time showed that
patients were more likely to report immediate recov-
ery while receiving HDF treatment (34.4% for HDF
vs 32.2% for HD; OR, 1.37; 95% confidence interval
[CI], 1.08-1.74; P 5 0.01; Fig 2A). Conversely, HDF
resulted in longer delayed recovery times (for HDF vs
HD, medians of 150 [IQR, 60-420] vs 1376 4.3
minutes, geometric means of 120 [IQR, 30-270] vs
1046 4.6 minutes, respectively; P , 0.001; Fig 2B).
Table S1 (provided as online supplementary material)
shows baseline characteristics comparing patients
who reported at least one immediate recovery time
with those who reported only delayed recovery times.
There was no interaction between treatments and
the order in which they were given (treatment effect)
for immediate (P 5 0.8) or delayed (P 5 0.6) recov-
ery times. Although there was no evidence of a dif-
ference in recovery time reporting between the first
and second period of the study (time effect) forTable 2. Delivered Treatment and Peritrea
Variable HD
Session length, min 250 6 17
Blood flow rate, mL/min 315 6 27
Ultrafiltration volume, mL 1,749 6 718 1,
Convection volume, L NA 2
Pretreatment SBP, mm Hg 145 6 21
Pretreatment DBP, mm Hg 69 6 12
Posttreatment SBP, mm Hg 126 6 20
Posttreatment DBP, mm Hg 64 6 10
Note: Unless otherwise indicated, values are given as mean 6 st
Abbreviations: DBP, diastolic blood pressure; HD, high-flux hemod
blood pressure.
4
delayed recovery times (OR for delayed recovery,
second vs first study period, 0.99; 95% CI, 0.89-1.09;
P 5 0.8), patients were more likely to report imme-
diate recovery during the first half of the study (OR
for immediate recovery, second vs first study period,
0.77; 95% CI, 0.61-0.98; P 5 0.04), regardless of
treatment (Tables S2 and S3).
A washout period was not possible given the nature
of the treatments. However, with regard to carryover
effect, the correlation between sessions decreased
quickly and was ,5% for both treatments after 9
sessions. To test for the influence of carryover effect,
analyses were repeated by removing up to and
including the first 9 sessions of each treatment. Im-
mediate, delayed, and overall recovery times
remained equivalent after these alterations (Table S4).
Secondary Outcomes
Symptomatic Hypotension
HDF was associated with an increased rate of
symptomatic hypotension compared to HD (8.0% vs
5.3%; RR, 1.52; 95% CI, 1.2-1.9; P , 0.001;
Table 3). Antihypertensive dosing was increased in 3
patients while on HD therapy and 1 patient while on
HDF therapy (P 5 0.6); similarly, dosing was
reduced in 3 patients while on HD therapy and 1
patient while on HDF therapy (P 5 0.6).
Clotting Risk
The intradialytic tendency to clotting was higher
during HDF than HD (1.8% vs 0.7%; RR, 2.7; 95%
CI, 1.5-5.0; P 5 0.002; Table 3). There was no dif-
ference in tinzaparin dosing (2,7736 147 and
2,740 6 140 units for HDF and HD, respectively;
P 5 0.9).
Laboratory Values
None of the prespecified laboratory measurements
showed statistically significant differences between
HDF andHD treatments (Table 4). Blood sampleswere
stored for additional analyses (eg. b2-microglobulin,tment Blood Pressure: HD Versus HDF
HDF Crossover P Data Available, %
2506 17 0.1 94
3136 28 0.6 93
7236 672 0.4 94
0.66 4.6 NA 82
1436 21 0.03 93
69 6 12 0.1 93
1256 18 0.08 93
63 6 10 0.1 93
andard deviation.
ialysis; HDF, hemodiafiltration; NA, not applicable; SBP, systolic
Am J Kidney Dis. 2016;-(-):---
Figure 2. Bar and density plots of
immediate and delayed recovery times
for high-flux hemodialysis (HD) and
hemodiafiltration (HDF). (A) Bar plot
shows percentage of recovery times
that were recorded as equal to zero mi-
nutes. (B) Density plot shows delayed
(.0 minute) recovery times for HD and





















































As shown in Table 4, there were small but statisti-
cally significant differences in serum albumin (3.2 vs
3.3 g/dL for HDF and HD, respectively; P , 0.001)
and chloride levels (101 vs 100 mEq/L for HDF and
HD; P 5 0.02).
Other Adverse Events
Other adverse events were grouped according to
those that may or may not have been related to blood
pressure (BP) changes or fluid shifts (Table 3).
Although the frequency of events not typically asso-
ciated with BP or fluid shifts was similar betweenTable 3. Adverse Events for H
Variable HD Sessions HD
Symptomatic hypotensiona 112 (5.2) 1
AEs potentially related to BP/fluid shiftsb 61 (3.0) 1
AEs not classically related to BP/fluid shiftsc 88 (4.3)
Extra tinzaparin dose(s) or clotting of circuitd 14 (0.7)
Note: Unless otherwise indicated, values are given as number o
treated as a single event. Odds ratios taking into account the crossov
Abbreviations: AE, adverse event; BP, blood pressure; CI, confide
RR, relative risk.
aDefined as a decrease in systolic BP $ 20 mm Hg requiring reduc
bolus or head-down tilt of dialysis chair.
bBreathlessness, cramp (normal BP), dizzy/lightheaded, fall, head
cAches in bones, arm pain, back pain, bleeding, constipation, dia
heavy legs, increased lethargy, infection (given antibiotics), itch, leg
vomiting.
dDefined as either an increase in venous pressure requiring additio
Am J Kidney Dis. 2016;-(-):---groups, there were more instances of events more
likely to be related to BP or fluid shifts during HDF
treatment compared to HD (5.3% vs 3.0%; RR, 1.8;
95% CI, 1.3-2.5; P , 0.001).
Quality-of-Life Scores
Patients completed KDQOL-SF, version 1.3, ques-
tionnaires19 during the study. Patients scored physical
health lower (33 6 10) than mental health (44 6 10)
at baseline. There was no difference in physical health
composite scores (33 6 9 for both HDF and HD;
P 5 0.9) or mental health composite scores (44 6 11
vs 43 6 12 for HDF and HD, respectively; P 5 0.6)
after 8 weeks of each treatment.
Withdrawals/Deaths
There were 9 withdrawals during the study, 2
occurring after randomization but before starting theD and HDF, Per Session
F Sessions RR (95% CI) P Data Available, %
68 (8) 1.52 (1.21-1.92) ,0.001 97
09 (5.3) 1.81 (1.33-2.46) ,0.001 93
87 (4.3) 1.00 (0.75-1.34) 0.9 93
37 (1.8) 2.68 (1.46-5.00) 0.002 97
f events (percentage). Multiple episodes within 1 session were
er design were also calculated and were almost identical to RRs.
nce interval; HD, high-flux hemodialysis; HDF, hemodiafiltration;
tion or cessation of ultrafiltration and/or need for intravenous fluid
ache, venous pressures erratic, clotted needle, or restless legs.
rrhea, feeling cold, feeling down, feeling hot, generally unwell,
pain, nausea, stomach pains, sweating, swollen abdomen, and
nal anticoagulant dosing or clotting of the extracorporeal circuit.
5
Table 4. Midweek Pretreatment Blood Test Results and Urea Clearance, HD Versus HDF
Variable HD HDF Crossover P Data Available, %
Hemoglobin, g/dL 11.56 1.3 11.36 1.3 0.1 92
WBC count, 3103/mL 7.36 2.6 7.46 2.7 0.5 92
Platelets, 3103/mL 2256 73 2266 79 0.7 92
C-Reactive protein,a mg/L 14 6 17 12 6 10 0.9 92
Calcium, mg/dL 9.66 0.4 9.66 0.8 0.4 92
Phosphate, mg/dL 5.06 1.2 5.06 1.2 0.7 92
PTH, pg/mL 7016 483 6666 474 0.2 88
Albumin, g/dL 3.36 0.3 3.26 0.3 ,0.001 92
Sodium, mEq/L 1376 2 1376 3 0.9 84
Potassium, mEq/L 4.86 0.6 4.86 0.6 0.6 84
Chloride, mEq/L 1006 2 1016 3 0.02 84
Bicarbonate, mEq/L 20 6 2 20 6 2 0.3 84
Urea reduction ratio 75 6 5 76 6 6 0.5 92
Kt/V 1.66 0.4 1.76 0.4 0.2 90
Creatinine, mg/dL 8.26 2.3 8.26 2.4 0.6 84
Vitamin B12,
a ng/L 4606 273 4916 360 0.3 89
Folate, ng/mL 23 6 6 24 6 6 0.5 92
Ferritin,a mg/L 3976 240 4196 272 0.3 92
Reticulocytes, 3103/mL 66 6 27 71 6 29 0.05 89
Note: Unless otherwise indicated, values are given as mean 6 standard deviation. Conversion factors for units: calcium in mg/dL to
mmol/L, 30.2495; creatinine in mg/dL to mmol/L, 388.4; folate in ng/mL to nmol/L, 32.266; glucose in mg/dL to mmol/L, 30.05551;
phosphate in mg/dL to mmol/L, 30.3229.
Abbreviations: HD, high-flux hemodialysis; HDF, hemodiafiltration; PTH, parathyroid hormone; WBC, white blood cells.
aData log transformed prior to statistical tests.
Smith et altrial as a result of emergency hospital admissions.
Four patients died during the study. Further details are
given in Table S5.
Maintenance of Blinding and Patient Preferences
Blinding to treatment was maintained in 84 of the
86 patients who completed the study. While still
blinded, these 84 patients were asked which treatment
they preferred; 52 had no preference, 21 preferred
HDF, and 11 preferred HD. Eight patients felt able to
guess the treatment order based on their symptoms; 5
were correct and 3 were incorrect.
DISCUSSION
This patient-blinded, randomized, controlled,
crossover trial showed no difference in the primary
outcome of patient-reported posttreatment recovery
time between HDF and HD (medians of 47.5 [IQR,
0-240] and 30 [IQR, 0-210] minutes, respectively;
P 5 0.9). However, recovery time data had a bimodal
distribution, with more than one-third of recovery
times being recorded as zero minutes (immediate).
Therefore, analysis of immediate recovery was per-
formed separately from delayed recovery, with inter-
esting yet disparate results. Treatment with HDF was
associated with a significantly higher chance of im-
mediate recovery (P 5 0.01), but resulted in signifi-
cantly longer recovery time than HD for those who
had delayed recovery (P , 0.001).
We hypothesize that inherent differences among
patients reporting immediate and delayed recovery6
times may have influenced treatment tolerance. For
example, patients with fewer comorbid conditions
may report more symptomatic benefit from enhanced
small- and middle-molecule clearance attributed to
convective treatments, whereas patients with more
comorbid conditions may tolerate HDF less well. A
recent subanalysis of the DOPPS cohort showed that
recovery time, based on a categorical measure at a
single time, was similar in patients on HDF and HD
therapy (OR, 1.08; 95% CI, 0.87-1.35).18 Interest-
ingly, longer recovery time was associated with
increased mortality, as well as adverse clinical fea-
tures such as older age, higher body mass index, and
diabetes.18 We found that patients who reported im-
mediate recovery were significantly more likely at
baseline to be lighter (73 vs 86 kg; P 5 0.008) and
active on the transplant waiting list (29% vs 6%;
P 5 0.009) than patients who reported only delayed
recovery times, but other baseline characteristics were
similar (Table S1).
Patient-reported posttreatment recovery time is
inherently subjective, difficult to measure robustly,
and at risk for reporting or recall bias. Our choice of
crossover design was made in the face of these po-
tential issues in order to abrogate the influence of
interpatient variability. The question “How long does
it take you to recover from a dialysis session” has
been validated as easy to understand and stable in the
face of retest, yet sensitive to alterations in treat-
ment,23 and this was the same question administered
to the DOPPS cohort.18 The former study asked theAm J Kidney Dis. 2016;-(-):---
Recovery Time in HD Versus HDFquestion at 3-month intervals (recording the answer as
a continuous variable), and in the latter study, the
question was asked once at the beginning of the study
and collected as a categorical variable. In order to
achieve sufficient granularity, we recorded recovery
time as a continuous variable; how this compares to a
categorical approach is not known. In addition, we
adapted the question asked of the study patients to
“How long did it take you to recover from your
previous treatment session” given that this was being
asked at every session. The differences noted between
treatment modalities in immediate and delayed re-
covery time reporting in this study suggest that this
approach was sufficiently sensitive to detect changes
in recovery time.
We found no difference in HRQoL scores between
HD and HDF, which is consistent with the result of
the overall primary outcome. Longer postdialysis re-
covery time has been associated with poorer HRQoL
scores.18,23 Additionally, associations have also been
drawn between lower HRQoL scores and patient
mortality.17,24,25
There was an increase in risk for intradialytic
clotting with HDF, which in the majority of cases was
mitigated by an increase in anticoagulant dose prior to
clotting of the circuit. Clotting resulting in the need to
change the circuit was infrequent, occurring in 0.62%
of HDF sessions and 0.38% of HD sessions. Post-
dilution HDF provides more efficient convective
clearance compared with predilution HDF, but has
previously been associated with an increase in clot-
ting events compared to HD.26 There was no differ-
ence in mean anticoagulant doses between treatments
in our study, perhaps due to the small number of
clotting events prompting an increase in subsequent
anticoagulant doses.
Unexpectedly, we found that HDF was associated
with increased symptomatic hypotension. Eighty
percent of these episodes were classed as mild,
requiring only cessation of ultrafiltration. There was
also a small reduction in pretreatment SBP in those
receiving HDF, whereas posttreatment SBP was
equivalent between treatments. Convective treatments
are often considered to have a hemodynamic advan-
tage over HD. This has been described in studies
comparing low-flux HD to hemofiltration or
HDF,27,28 but not in a study in which both modalities
were performed under matched conditions,29 and we
are not aware of blinded trials analyzing this outcome.
When comparing HD to HDF, Ok et al10 found no
difference in symptomatic hypotension (defined as a
decrease in SBP. 30 mm Hg requiring saline solu-
tion infusion), and in the ESHOL (Estudio de
Supervivencia de Hemodiafiltración On-Line) study,
the incidence of symptomatic hypotension (not
clearly defined) was lower in the HDF group (rateAm J Kidney Dis. 2016;-(-):---ratio, 0.72; 95% CI, 0.68-0.77; P , 0.001).13 The
reasons behind the disparate findings are unclear, but
importantly, in our study, there were no significant
changes in antihypertensive treatment, ultrafiltration
volume, blood flow, or dialysis dose between
treatments.
With regard to blood parameters, it is worth high-
lighting the small reduction in serum albumin levels
during HDF treatment compared to HD (3.2 vs 3.3 g/
dL, respectively; P , 0.001). Data for serum albumin
levels in previous studies comparing HDF to HD are
variable. Ok et al10 found that albumin levels were
lower in the HDF group, whereas in ESHOL, there
was no difference between treatments.13 However,
serum albumin levels decreased in both groups
compared to baseline over the course of both these
randomized studies.10,13 Even small reductions in
serum albumin levels are strongly associated with
reduced survival in HD patients.30 Therefore, it is
important to be aware of such changes, particularly in
the presence of pre-existing hypoalbuminemia.
In light of these findings, it is conceivable that
more frequent episodes of hypotension and lower
serum albumin levels may have influenced recovery
time adversely in the HDF group. However, we found
no difference in results of the primary outcome when
adjustments were made for BP and serum albumin
level (Table S4).
The success of patient blinding exceeded our ex-
pectations and is worthy of note; this should be
considered a realistic strategy for future studies
investigating extracorporeal treatments. Due to the
practicalities of administering these treatments,
double-blinding was not possible, and the treating
nurses were responsible for collecting end point data
from patients. However, statistical analyses were
performed on anonymized allocation-blinded data.
Inclusion criteria were designed to be as broad as
possible to serve as a representative cohort of long-
term HD patients. It may be that this in part limited
our ability to achieve HDF convection volumes
described in previous studies. For example, in our
study, the arteriovenous fistula rate (68%) was lower
than in the ESHOL online-HDF group (89%), as
were mean blood flow rates (313 mL/min in our
study vs 389 mL/min after 36 months in the ESHOL
online-HDF group).13 These factors, in addition to
treatment time, are known to be important in deter-
mining achieved convection volumes.15,31 In our
study, mean treatment time was 250 minutes, longer
than the 237 minutes reported after 36 months in the
ESHOL online-HDF group,13 suggesting that blood
flow rate was one of the most important factors
limiting achieved convection volume.
The single-center (although multiple satellite unit)
design is a limitation. Additionally, the predominance7
Smith et alof patients of European ancestry, although represen-
tative of our case-mix, will be less applicable in other
regions. It is also possible that the nursing staff’s
longer term experience with HD compared to HDF
could have had an influence on results. However, this
situation is likely to be the case in most nephrology
units, and crossover analyses demonstrated more im-
mediate recovery times for both treatments during the
first treatment period, with no difference in delayed
recovery times between treatment periods, suggesting
that increasing staff experience in delivering HDF
treatment is likely to have had minimal influence.
To our knowledge, this is the first RCT to examine
recovery time in the setting of HD and HDF, and we
found no overall difference between treatments.
However, HDF was associated with both more epi-
sodes of immediate recovery and longer recovery
time if recovery was not immediate. Although more
recent data may suggest a beneficial role for online
HDF with high convection volumes, many patients
may be unable to achieve such convection volumes
and therefore neither treatment is definitively supe-
rior for all patients.32 The overall result of our pri-
mary outcome is consistent with the findings of
previous observational studies18,24,25; however, it is
difficult to infer which of the many variables asso-
ciated with extracorporeal treatments may be
responsible for effects on recovery time or mortality.
For example, more frequent (6 times per week) HD
has been associated with a reduction in recovery time
compared to thrice-weekly HD,33 as well as im-
provements in areas such as BP and serum phosphate
control, left ventricular mass, and HRQoL.34-36
Whether this leads to improvements in patient sur-
vival remains a point of debate.37-40 With this in
mind and in light of the association between recovery
time and mortality as identified in the DOPPS
cohort,18 a large-scale, blinded, multicenter RCT of
HDF and HD powered to examine morbidity and
mortality outcomes while taking into account re-
covery time reporting and quality-of-life scores
across a representative patient group would be of
benefit.
Debate remains regarding the clinical case for HDF
over HD. Patient preference and shared decision
making are increasingly prioritized in clinical prac-
tice, and these data may further inform the discussion
around choice of extracorporeal treatments.
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